SciRhom GmbH raises €63M in Series A funding for autoimmune disorder therapeutics.
SciRhom GmbH secured €63M in Series A financing, co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners. The funds aim to accelerate and broaden the impact of the innovative therapeutic strategy in autoimmune disorders. SciRhom's first clinical study of SR-878, a specific monoclonal antibody for iRhom2, is expected to begin in 2H 2024, targeting TACE/ADAM17, a key driver of autoimmune disease-related signaling pathways.
July 09, 2024
3 Articles